Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04760704

Covid-19 Vaccine Response in Elderly Subjects — MONITOCOVAGING  

Covid19 Vaccine Clinical Trial

Official title:
Evaluation of the Immunogenicity of mRNA BNT162b2 (COMIRNATY®) Vaccine in Elderly Subjects by Monitoring the Specific Cellular and Humoral Response.

Clinical Trial Summary

The objective of this research is to assess the amplitude and quality of the vaccine response against SARS-CoV-2, defined here by its characteristics established at 3 months, and its persistence over time, defined here at 9 months, in subjects residing in medical establishment for dependent elderly persons, compared to immunocompetent subjects aged 40 to 65 years (control subjects for vaccination over the same period).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04760704
Study type Observational
Source University Hospital, Lille
Contact
Status Active, not recruiting
Phase
Start date February 19, 2021
Completion date January 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT05079633 - A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults Phase 4
Completed NCT05011526 - A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults Phase 3
Completed NCT04822025 - A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults Phase 2
Completed NCT04818892 - Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease
Completed NCT04951388 - A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents Phase 2
Not yet recruiting NCT04730895 - Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety. Phase 1/Phase 2
Completed NCT05048849 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study Phase 2
Completed NCT04765436 - PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64 Phase 1
Completed NCT04695652 - A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult Phase 2
Withdrawn NCT05029245 - IntraDermal Versus Intramuscular Comirnaty® Efficacy Study Phase 3
Completed NCT05038618 - A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study Phase 2
Completed NCT05175742 - PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine. Phase 2
Recruiting NCT04834869 - COVID-19 Vaccines Safety Tracking (CoVaST)